Subtype
Breast Adenocarcinoma
CI-CAN-00002035Explore in graph →
686 active trials9 approved drugs104 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002035Explore in graph →
Clinical trials
1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (278)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01805076 | MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer | completed | Phase 3 | 319 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04085276 | Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment(TORCHLIGHT) | completed | Phase 3 | 531 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 |
| Apr 16, 2026 |
| clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT04148911 | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer(EL1SSAR) | completed | Phase 3 | 184 | Hoffmann-La RocheINDUSTRY | 13 | Dec 26, 2025 | clinicaltrials |
| NCT00757302 | Intraoperative Gamma Camera for Breast Cancer Surgery | completed | Phase 3 | 110 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02926196 | Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab(A-Brave) | completed | Phase 3 | 474 | Istituto Oncologico Veneto IRCCSOTHER | 2 | Dec 12, 2025 | clinicaltrials |
| NCT03371017 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer(IMpassion132) | completed | Phase 3 | 595 | Hoffmann-La RocheINDUSTRY | 28 | Nov 12, 2025 | clinicaltrials |
| NCT03036488 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | completed | Phase 3 | 1,174 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Oct 29, 2025 | clinicaltrials |
| NCT03588091 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | completed | Phase 3 | 355 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02003209 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | completed | Phase 3 | 315 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2025 | clinicaltrials |
| NCT00769379 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | completed | Phase 3 | 2,014 | National Cancer Institute (NCI)NIH | 4 | Jun 12, 2025 | clinicaltrials |
| NCT05555706 | Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 2 / Phase 3 | 62 | Shanghai Jiaolian Drug Research and Development Co., LtdINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT02819518 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | completed | Phase 3 | 882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2024 | clinicaltrials |
| NCT03013504 | A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients(TROIKA) | completed | Phase 3 | 503 | Prestige Biopharma LimitedINDUSTRY | 13 | Nov 6, 2024 | clinicaltrials |
| NCT04957212 | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer | completed | Phase 3 | 214 | CinnagenINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT04613674 | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | completed | Phase 3 | 441 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT02620280 | Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1(NeoTRIPaPDL1) | completed | Phase 3 | 278 | Fondazione MichelangeloOTHER | 7 | Mar 6, 2024 | clinicaltrials |
| NCT06107790 | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer | completed | Phase 3 | 570 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer(IMpassion031) | completed | Phase 3 | 333 | Hoffmann-La RocheINDUSTRY | 13 | Oct 26, 2023 | clinicaltrials |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | completed | Phase 3 | 338 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Oct 26, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT03556358 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | completed | Phase 3 | 809 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Jan 14, 2022 | clinicaltrials |
| NCT02555657 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | completed | Phase 3 | 622 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 10, 2021 | clinicaltrials |
| NCT02324088 | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer(PEGASE07) | completed | Phase 3 | 174 | UNICANCEROTHER | 0 | Feb 21, 2021 | clinicaltrials |
| NCT00005970 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | completed | Phase 3 | 3,436 | National Cancer Institute (NCI)NIH | 4 | Aug 14, 2020 | clinicaltrials |
| NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)(GeparSepto) | completed | Phase 3 | 1,229 | GBG Forschungs GmbHOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT01216111 | Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) | completed | Phase 3 | 647 | Fudan UniversityOTHER | 0 | May 19, 2020 | clinicaltrials |
| NCT02961790 | Oxybutynin Chloride in Managing Hot Flashes | completed | Phase 3 | 150 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00390455 | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | completed | Phase 3 | 295 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT00869206 | Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | completed | Phase 3 | 1,822 | Alliance for Clinical Trials in OncologyOTHER | 2 | Nov 7, 2018 | clinicaltrials |
| NCT02225470 | Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 530 | Eisai Co., Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | completed | Phase 3 | 961 | GBG Forschungs GmbHOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00003440 | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | completed | Phase 3 | 580 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01508546 | Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer | completed | Phase 3 | 565 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 12, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 26, 2026source: clinicaltrials